Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$208.24 -0.1%	$194.10	$163.81 ▼ $218.66	$367.87B	0.5	6.61 million shs	3.46 million shs
IRWD Ironwood Pharmaceuticals	$1.26 -0.8%	$0.86	$0.53 ▼ $5.21	$204.66M	0.33	2.81 million shs	415,610 shs
MYGN Myriad Genetics	$5.93 +2.1%	$5.19	$3.76 ▼ $29.30	$551.76M	1.89	1.73 million shs	595,678 shs
VSTM Verastem	$9.29 +4.4%	$5.93	$2.34 ▼ $9.43	$571.75M	0.83	1.83 million shs	2.61 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.45%	+1.22%	+9.62%	+13.95%	+5.57%
IRWD Ironwood Pharmaceuticals	0.00%	+18.69%	+55.58%	+114.38%	-74.80%
MYGN Myriad Genetics	-1.36%	+5.44%	+30.56%	+34.18%	-78.99%
VSTM Verastem	-0.89%	+14.25%	+44.95%	+16.95%	+241.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7033 of 5 stars	2.5	4.0	3.3	3.9	3.3	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.5994 of 5 stars	3.1	5.0	0.0	3.4	3.8	0.8	1.9
MYGN Myriad Genetics	3.6554 of 5 stars	3.1	2.0	0.0	4.1	2.7	1.7	0.0
VSTM Verastem	3.147 of 5 stars	3.5	3.0	0.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.96	Moderate Buy	$214.95	3.22% Upside
IRWD Ironwood Pharmaceuticals	2.14	Hold	$4.94	292.06% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	110.03% Upside
VSTM Verastem	3.00	Buy	$13.29	43.01% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, MYGN, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/25/2025	VSTM Verastem	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/12/2025	VSTM Verastem	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $13.00
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/1/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$250.00 ➝ $255.00
8/1/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$216.00 ➝ $227.00
8/1/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$227.00 ➝ $236.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.53	$14.98 per share	13.90	($0.08) per share	-2,602.99
IRWD Ironwood Pharmaceuticals	$351.41M	0.58	$0.05 per share	25.68	($1.90) per share	-0.66
MYGN Myriad Genetics	$832.90M	0.66	$1.01 per share	5.89	$4.17 per share	1.42
VSTM Verastem	$2.14M	267.55	N/A	N/A	$0.59 per share	15.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	99.16	14.90	1.33	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.05	N/A	5.04	N/A	-2.25%	-2.46%	2.19%	11/6/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.28	N/A	N/A	N/A	N/A	-2,003.62%	-119.85%	11/5/2025 (Estimated)

Latest IRWD, ABBV, MYGN, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IRWD Ironwood Pharmaceuticals	-$0.02	$0.14	+$0.16	$0.14	$62.02 million	$85.24 million
8/7/2025	Q2 2025	VSTM Verastem	-$0.64	-$0.39	+$0.25	-$0.39	$6.01 million	$2.14 million
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.15%	N/A	312.38%	53 Years
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Latest IRWD, ABBV, MYGN, and VSTM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
IRWD Ironwood Pharmaceuticals	N/A	0.82	0.82
MYGN Myriad Genetics	N/A	1.42	1.28
VSTM Verastem	2.06	3.46	3.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
IRWD Ironwood Pharmaceuticals	N/A
MYGN Myriad Genetics	99.02%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
IRWD Ironwood Pharmaceuticals	12.70%
MYGN Myriad Genetics	2.10%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.77 billion	Optionable
IRWD Ironwood Pharmaceuticals	220	162.43 million	141.81 million	Optionable
MYGN Myriad Genetics	2,700	93.05 million	91.09 million	Optionable
VSTM Verastem	50	61.55 million	60.25 million	Optionable

IRWD, ABBV, MYGN, and VSTM Headlines

Recent News About These Companies

Verastem Oncology to Present at Upcoming Investor Conferences

August 27 at 7:11 AM | mms.businesswire.com

Verastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLC

August 26 at 7:38 AM | marketbeat.com

Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?

August 25 at 12:50 PM | tipranks.com

Balyasny Asset Management L.P. Increases Stake in Verastem Inc

August 20, 2025 | gurufocus.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $13.29

August 20, 2025 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 18, 2025 | marketbeat.com

Zacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 17, 2025 | marketbeat.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | insidermonkey.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | finance.yahoo.com

Verastem price target lowered to $14 from $16 at Mizuho

August 15, 2025 | msn.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results

August 14, 2025 | za.investing.com

Verastem Unveils Promising VS-7375 Study Results

August 14, 2025 | msn.com

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

August 13, 2025 | businesswire.com

Verastem Inc. Earnings Call: Positive Outlook with Key Achievements

August 13, 2025 | msn.com

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 11, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Releases Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Price Target Raised to $13.00

August 10, 2025 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 8, 2025 | seekingalpha.com

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline

August 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRWD, ABBV, MYGN, and VSTM Company Descriptions

AbbVie NYSE:ABBV

$208.24 -0.12 (-0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$208.20 -0.03 (-0.02%)

As of 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ironwood Pharmaceuticals NASDAQ:IRWD

$1.26 -0.01 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 0.00 (-0.32%)

As of 07:51 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Myriad Genetics NASDAQ:MYGN

$5.93 +0.12 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$6.14 +0.21 (+3.46%)

As of 07:47 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Verastem NASDAQ:VSTM

$9.29 +0.39 (+4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$9.17 -0.12 (-1.29%)

As of 06:54 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time